November 23, 2016 - By Peter Erickson
In view of the sell Laura Leber made she is in the traders attention today. The Chief Communication Officer of Genomic Health Inc and an insider, made a sale of 7,068 shares worth $224,266 US Dollars. The average price was $31.7 per share. This deal was conducted on 23/11/2016. A public form which was filed with the U.S. Security and Exchange Commission and available here, reveals an extra information for the deal. Laura Leber now has in hand 14,331 shares or 0.04% of Genomic Health Inc’s market cap.
Out of 6 analysts covering Genomic Health (NASDAQ:GHDX), 3 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 50% are positive. $44 is the highest target while $25 is the lowest. The $32.50 average target is 3.37% above today’s ($31.44) stock price. Genomic Health has been the topic of 17 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Underweight” rating given on Wednesday, September 2 by Barclays Capital. The stock of Genomic Health, Inc. (NASDAQ:GHDX) has “Outperform” rating given on Thursday, November 19 by Cowen & Co. Raymond James upgraded the stock to “Market Perform” rating in Friday, August 28 report. The stock of Genomic Health, Inc. (NASDAQ:GHDX) earned “Buy” rating by UBS on Monday, November 23. The stock of Genomic Health, Inc. (NASDAQ:GHDX) earned “Outperform” rating by Raymond James on Wednesday, November 4. The firm has “Buy” rating given on Wednesday, January 6 by Canaccord Genuity. The rating was maintained by Jefferies on Wednesday, August 17 with “Hold”. Canaccord Genuity maintained it with “Hold” rating and $26 target price in Wednesday, August 5 report. Zacks upgraded the stock to “Sell” rating in Monday, August 24 report. The stock has “Neutral” rating given by Piper Jaffray on Monday, January 11.
Insitutional Activity: The institutional sentiment decreased to 1.4 in 2016 Q2. Its down 0.16, from 1.56 in 2016Q1. The ratio fall, as 11 funds sold all Genomic Health, Inc. shares owned while 30 reduced positions. 19 funds bought stakes while 45 increased positions. They now own 29.46 million shares or 0.97% less from 29.75 million shares in 2016Q1.
Proshare Advsr Lc has invested 0.01% of its portfolio in Genomic Health, Inc. (NASDAQ:GHDX). Moreover, Parametric Portfolio Assoc Limited has 0% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 19,244 shares. Schwab Charles Inv Mgmt accumulated 0% or 127,652 shares. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. First Manhattan holds 200 shares or 0% of its portfolio. State Farm Mutual Automobile reported 317,240 shares or 0.01% of all its holdings. Moreover, Blackrock Inc has 0% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 53,585 shares. Diam Company Ltd last reported 0.01% of its portfolio in the stock. Millennium Mngmt Lc last reported 836,285 shares in the company. National Bank & Trust Of America De accumulated 0% or 13,748 shares. Fmr Ltd Liability reported 525,148 shares or 0% of all its holdings. California State Teachers Retirement Systems has 39,167 shares for 0% of their US portfolio. Barclays Pcl owns 27 shares or 0% of their US portfolio. Acuta Capital Limited Com, a California-based fund reported 48,800 shares. American International Group, a New York-based fund reported 10,753 shares.
Insider Transactions: Since June 6, 2016, the stock had 1 insider buy, and 15 insider sales for $676,665 net activity. Cole G Bradley sold $133,223 worth of stock or 5,000 shares. BAKER FELIX had bought 100,000 shares worth $2.70M. On Monday, August 8 Vaughn James J sold $86,222 worth of the stock or 3,000 shares. Shares for $158,569 were sold by Shak Steven. Popovits Kimberly J sold $153,423 worth of Genomic Health, Inc. (NASDAQ:GHDX) on Thursday, November 3.
About 108,714 shares traded hands. Genomic Health, Inc. (NASDAQ:GHDX) has risen 13.07% since April 21, 2016 and is uptrending. It has outperformed by 7.74% the S&P500.
Genomic Health, Inc. is a healthcare company, which provides genomic diagnostic tests for the treatment of early stage cancer. The company has a market cap of $1.05 billion. The Firm offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ and a Genomic Prostate Score for prostate cancer. It currently has negative earnings. The Company’s Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor.
According to Zacks Investment Research, “Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.”
Analysts await Genomic Health, Inc. (NASDAQ:GHDX) to report earnings on February, 8.
More notable recent Genomic Health, Inc. (NASDAQ:GHDX) news were published by: Fool.com which released: “Genomic Health, Inc.: Almost at Breakeven” on November 03, 2016, also Fool.com with their article: “Genomic Health, Inc. Earnings: Waiting for (More) Reimbursement” published on May 11, 2016, Fool.com published: “Genomic Health, Inc. Pushes Toward Profitability” on August 04, 2016. More interesting news about Genomic Health, Inc. (NASDAQ:GHDX) were released by: Fool.com and their article: “Genomic Health, Inc. Eyes Profitability” published on February 11, 2016 as well as Fool.com‘s news article titled: “Why Genomic Health, Inc. Earned a Higher Share Price” with publication date: May 05, 2016.
Genomic Health, Inc., incorporated on August 22, 2000, is a healthcare company, which provides genomic diagnostic tests for the treatment of early stage cancer. The Firm offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score (GPS) for prostate cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.